Home

Report

Biosimilars in the United States 2023–2027

Biosimilars in the United States 2023–2027

IQVIA
Pages 41 Pages

This comprehensive report reviews the evolution of the U.S. biosimilars market, documenting progress in approvals, launches, and cost savings. Despite increased availability, uptake varies significantly by therapy area and payer strategy. The report analyzes pricing trends, formulary practices, and provider behavior, highlighting how rebate structures and contracting limit broader adoption. It concludes that while biosimilars have delivered meaningful savings, further policy and market reforms are needed to ensure long-term sustainability and patient access.

Join for free to read

You Might Also Like


United States Air Force
Case Study United States Air Force
Micro Focus

Medicine Spending and Affordability in the United States Global Oncology Trends
Report Medicine Spending and Affordability in the United States Global…
IQVIA

TV station, United States
Case Study TV station, United States
ACE (Advanced Coatings Engineering)

A Southwestern United States Credit Union
Case Study A Southwestern United States Credit Union
Verafin

More from IQVIA


Medicine Spending and Affordability in the United States Global Oncology Trends
Report Medicine Spending and Affordability in the United States Global…
IQVIA

Prescription Opioid Trends in the United States
Report Prescription Opioid Trends in the United States
IQVIA

Medicine Spending and Affordability in the United States Orphan Drugs in the United States
Report Medicine Spending and Affordability in the United States Orphan…
IQVIA

Medicine Spending and Affordability in the United States Medicine Spending and Affordability in the United States
Report Medicine Spending and Affordability in the United States…
IQVIA
© 2026 Contentree.  All Rights Reserved   |   Privacy and Cookies   |   Legal   |   Do not sell my info